TransEnterix, Inc. to Join the Russell 2000® Index
25 Junio 2018 - 5:55AM
Business Wire
TransEnterix, Inc. (NYSE American:TRXC), a medical device
company that is digitizing the interface between surgeons and
patients to improve minimally invasive surgery, today announced
that the company will be added to the Russell 2000® Index at the
conclusion of the Russell US Indexes annual reconstitution,
effective after the U.S. market opens on June 25, 2018.
The annual reconstitution of the broad-market Russell Indexes
captures the largest U.S. stocks, ranking them by total market
capitalization. The largest 1,000 companies in this ranking
comprise the Russell 1000® Index and the next 2,000 companies
constitute the Russell 2000® Index, which together comprise the
Russell 3000® Index. Membership in the index is effective until the
Index’s next annual reconstitution and also results in inclusion in
the appropriate growth and value style indexes.
“We are excited to be joining the Russell 2000 Index, which puts
us alongside many of the largest public companies in the U.S.” said
Todd M. Pope, TransEnterix CEO. “We have worked diligently to
create value for our shareholders, and we believe our inclusion
represents a great opportunity to continue to do so by increasing
our visibility and exposure to investors.”
Russell US Indexes are widely used by investment managers and
institutional investors as the basis for index funds and as
benchmarks for active investment strategies. Approximately $9
trillion in assets are benchmarked against Russell US Indexes.
Russell US Indexes are part of FTSE Russell, a leading global index
provider.
For more information on the Russell 2000® Index and the Russell
US Indexes reconstitution, go to the “Russell Reconstitution”
section on the FTSE Russell website.
About TransEnterix, Inc.
TransEnterix is a medical device company that is digitizing the
interface between the surgeon and the patient to improve minimally
invasive surgery by addressing the clinical and economic challenges
associated with current laparoscopic and robotic options in today's
value-based healthcare environment. The Company is focused on the
commercialization of the Senhance™ Surgical System, which digitizes
laparoscopic minimally invasive surgery. The system allows for
robotic precision, haptic feedback, surgeon camera control via eye
sensing and improved ergonomics while offering responsible
economics. The Senhance Surgical System is available for sale in
the US, the EU and select other countries. For more information,
visit www.transenterix.com.
About FTSE Russell
FTSE Russell is a leading global index provider creating and
managing a wide range of indexes, data and analytic solutions to
meet client needs across asset classes, style and strategies.
Covering 98% of the investable market, FTSE Russell indexes offer a
true picture of global markets, combined with the specialist
knowledge gained from developing local benchmarks around the
world.
FTSE Russell index expertise and products are used extensively
by institutional and retail investors globally. Approximately $16.2
trillion is currently benchmarked to FTSE Russell indexes. For over
30 years, leading asset owners, asset managers, ETF providers and
investment banks have chosen FTSE Russell indexes to benchmark
their investment performance and create investment funds, ETFs,
structured products and index-based derivatives. FTSE Russell
indexes also provide clients with tools for asset allocation,
investment strategy analysis and risk management.
A core set of universal principles guides FTSE Russell index
design and management: a transparent rules-based methodology is
informed by independent committees of leading market participants.
FTSE Russell is focused on index innovation and customer
partnership applying the highest industry standards and embracing
the IOSCO Principles. FTSE Russell is wholly owned by London Stock
Exchange Group.
Forward-Looking Statements
This press release includes statements relating to the Senhance
Surgical System and our current regulatory and commercialization
plans for this product. These statements and other statements
regarding our future plans and goals constitute "forward looking
statements" within the meaning of Section 27A of the Securities Act
of 1933 and Section 21E of the Securities Exchange Act of 1934, and
are intended to qualify for the safe harbor from liability
established by the Private Securities Litigation Reform Act of
1995. Such statements are subject to risks and uncertainties that
are often difficult to predict, are beyond our control and which
may cause results to differ materially from expectations and
include whether our inclusion in the Russell 2000 Index represents
a great opportunity to create value for our shareholders by
increasing our visibility and exposure to investors. For a
discussion of the risks and uncertainties associated with
TransEnterix's business, please review our filings with the
Securities and Exchange Commission (SEC), including our Annual
Report on Form 10-K filed on March 8, 2018 and our other filings we
make with the SEC. You are cautioned not to place undue reliance on
these forward looking statements, which are based on our
expectations as of the date of this press release and speak only as
of the origination date of this press release. We undertake no
obligation to publicly update or revise any forward-looking
statement, whether as a result of new information, future events or
otherwise.
For more information, visit www.ftserussell.com
View source
version on businesswire.com: https://www.businesswire.com/news/home/20180625005234/en/
For TransEnterix, Inc.Investors:Mark Klausner,
+1-443-213-0501invest@transenterix.comorMedia:Joanna Rice, +
1-951-751-1858joanna@greymattermarketing.com
TransEnterix (AMEX:TRXC)
Gráfica de Acción Histórica
De Ago 2024 a Sep 2024
TransEnterix (AMEX:TRXC)
Gráfica de Acción Histórica
De Sep 2023 a Sep 2024